Cannabinoid receptor-2 and HIV-associated neurocognitive disorders

Journal of Neuroimmune Pharmacology

Volumn 9, Issue 4, 2014, Pages 447-453

  Purohit, Vishnudutt ^a   Rapaka, Rao S ^a   Rutter, Joni ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Blood brain barrier; Cannabinoid receptor type 2; Highly active antiretroviral therapy; HIV associated neurocognitive disorders; Macrophages and microglia; Neuroinflammation

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CHEMOKINE; GLYCOPROTEIN GP 120; NEUROTOXIN; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CANNABINOID; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR; VIRAL PROTEIN;

BLOOD BRAIN BARRIER; COCAINE DEPENDENCE; DENDRITE; DISEASE SEVERITY; DOWN REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MEMBRANE PERMEABILITY; MICROGLIA; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SYNAPSE; VIREMIA; VIRUS INHIBITION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; COGNITIVE DEFECT; COMPLICATION; DENDRITIC SPINE; HUMAN IMMUNODEFICIENCY VIRUS; INFLAMMATION; MACROPHAGE ACTIVATION; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CANNABINOIDS; CHEMOKINES; COCAINE-RELATED DISORDERS; COGNITION DISORDERS; DENDRITIC SPINES; DOWN-REGULATION; GENE PRODUCTS, TAT; HIV; HIV INFECTIONS; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; NERVE DEGENERATION; RECEPTOR, CANNABINOID, CB2; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84906343750     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-014-9554-0     Document Type: Review

References (70)

1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139:258-266
2. Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S, Noonan DM (1998) Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem 273:15895-15900 (Pubitemid 28311351)
3. Alfahad TB, Nath A (2013) Update on HIV-associated neurocognitive disorders. Current neurology and neuroscience reports. PMC 13(387):3784616
4. An SF, Groves M, Gray F, Scaravilli F (1999) Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol 58:1156-1162 (Pubitemid 29519839)
5. Aracil-Fernandez A, Trigo JM, Garcia-Gutierrez MS, Ortega-Alvaro A, Ternianov A, Navarro D, Robledo P, Berbel P, Maldonado R, Manzanares J (2012) Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB(2) receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 37:1749-1763. PMC: 3358745
6. Ardila A, Rosselli M, Strumwasser S (1991) Neuropsychological deficits in chronic cocaine abusers. Int J Neurosci 57:73-79
7. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Bales RA, Ethisham A, Greenberg RN, Berger JR (2004) Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 10:223-232 (Pubitemid 39136617)
8. Beatty WW, Katzung VM, Moreland VJ, Nixon SJ (1995) Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend 37:247-253
9. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K, Collaboration C (2008) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 63:213-221 (Pubitemid 351355300)
10. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35:3135-3141
11. Clifford DB, Ances BM (2013) HIV-associated neurocognitive disorder. Lancet Infect Dis 13:976-986
12. Costantino CM, Gupta A, Yewdall AW, Dale BM, Devi LA, Chen BK (2012) Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PloS one 7:e33961. PMC: 3309010
13. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA (1992) Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42:1736-1739
14. de Paulis A, De Palma R, Di Gioia L, Carfora M, Prevete N, Tosi G, Accolla RS, Marone G (2000) Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI + cells. J Immunol 165:7171-7179 (Pubitemid 32001194)
15. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M (2007) Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 196:1779-1783 (Pubitemid 351411938)
16. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Journal of neuroinflammation 2:29. PMC: 1352348
17. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ, Hauser KF (2006) HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 53:132-146, PMC: 3077280
18. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41:161-168 (Pubitemid 36262193)
19. Fiala M, Gan XH, Zhang L, House SD, Newton T, Graves MC, Shapshak P, Stins M, Kim KS, Witte M, Chang SL (1998) Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? Adv Exp Med Biol 437:199-205 (Pubitemid 28350097)
20. Fitting S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise LE, Fox MA, Su J, Medina AE, Krahe TE, Knapp PE, Guido W, Hauser KF (2013) Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol Psychiatry 73:443-453, PMC: 3570635
21. Fraga D, Raborn ES, Ferreira GA, Cabral GA (2011) Cannabinoids inhibit migration of microglial-like cells to the HIV protein Tat. J NeuroImmune Pharm: Off J Soc NeuroImmune Pharm 6:566-577
22. Gannon P, Khan MZ, Kolson DL (2011) Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 24:275-283, PMC: 3683661
23. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5:69-81 (Pubitemid 40070332)
24. Gorantla S, Makarov E, Roy D, Finke-Dwyer J, Murrin LC, Gendelman HE, Poluektova L (2010) Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 5:456-468, PMC: 3109320
25. Grant I (2008) Neurocognitive disturbances in HIV. Int Rev Psychiatry 20:33-47
26. Heaton RK (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087-2096, PMC: 2995535
27. Kim BO, Liu Y, Zhou BY, He JJ (2004) Induction of C chemokine XCL1 (lymphotactin/single C motif-1 alpha/activation-induced, T cell-derived and chemokine-related cytokine) expression by HIV-1 Tat protein. J Immunol 172:1888-1895 (Pubitemid 38116839)
28. Kim HJ, Martemyanov KA, Thayer SA (2008a) Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. The Journal of neuroscience : the official journal of the Society for Neuroscience 28:12604-12613, PMC: 2678679
29. Kim HJ, Waataja JJ, Thayer SA (2008b) Cannabinoids inhibit network-driven synapse loss between hippocampal neurons in culture. The Journal of pharmacology and experimental therapeutics 325:850-858, PMC: 2398764
30. Kim HJ, Shin AH, Thayer SA (2011) Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss. Mol Pharmacol 80:357-366, PMC: 3164336
31. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE (2009) A coat ofmany colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 64:133-145, PMC: 2784686
32. Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE (2010) HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis 37:542-548, PMC: 2840259
33. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S (1997) Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 159:4077-4083 (Pubitemid 127469666)
34. Larrat EP, Zierler S (1993) Entangled epidemics: cocaine use and HIV disease. J Psychoactive Drugs 25:207-221 (Pubitemid 23298776)
35. Levine AJ, Hardy DJ, Miller E, Castellon SA, Longshore D, Hinkin CH (2006) The effect of recent stimulant use on sustained attention in HIV-infected adults. J Clin Exp Neuropsychol 28:29-42 (Pubitemid 43207238)
36. Lu TS, Avraham HK, Seng S, Tachado SD, Koziel H, Makriyannis A, Avraham S (2008) Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol 181:6406-6416, PMC: 3735224
37. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3:e46, PMC: 1847689
38. McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699-714
39. Meade CS, Conn NA, Skalski LM, Safren SA (2011) Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med 34:128-138, PMC: 3049963
40. Mestre L, Docagne F, Correa F, Loria F, Hernangomez M, Borrell J, Guaza C (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40:258-266
41. Miller AM, Stella N (2008) CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153:299-308, PMC: 2219538
42. Minghetti L, Visentin S, Patrizio M, Franchini L, Ajmone-Cat MA, Levi G (2004) Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem Res 29:965-978 (Pubitemid 39011346)
43. Mitola S, Sozzani S, Luini W, Primo L, Borsatti A, Weich H, Bussolino F (1997) Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 90:1365-1372 (Pubitemid 27355407)
44. Molina PE, Winsauer P, Zhang P, Walker E, Birke L, Amedee A, Stouwe CV, Troxclair D, McGoey R, Varner K, Byerley L, LaMotte L (2011) Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retrovir 27:585-592, PMC: 3131805
45. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105:3879-3884, PMC: 2268833
46. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J NeuroImmune Pharm: Off J Soc NeuroImmune Pharm 1:223-236 (Pubitemid 44244128)
47. Peterson PK, Gekker G, Hu S, Cabral G, Lokensgard JR (2004) Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol 147:123-126 (Pubitemid 38114961)
48. Pini A, Mannaioni G, Pellegrini-Giampietro D, Passani MB, Mastroianni R, Bani D, Masini E (2012) The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke. Curr Drug Targets 13:984-993
49. Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 24:224-237 (Pubitemid 37194547)
50. Puffenbarger RA, Boothe AC, Cabral GA (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29:58-69 (Pubitemid 30031134)
51. Raborn ES, Cabral GA (2010) Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor. J Pharmacol Exp Ther 333:319-327, PMC: 2846023
52. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P (2007) CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyteendothelial adhesion. American journal of physiology Heart and circulatory physiology 293:2210-2218, PMC: 2229632
53. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son YJ, Persidsky Y (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. The Journal of neuroscience : the official journal of the Society for Neuroscience 32: 4004-4016, PMC: 3325902
54. Ramirez SH, Reichenbach NL, Fan S, Rom S, Merkel SF, Wang X, Ho WZ, Persidsky Y (2013) Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. J Leukoc Biol 93:801-810, PMC: 3629438
55. Rock RB, Gekker G, Hu S, Sheng WS, Cabral GA, Martin BR, Peterson PK (2007) WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J NeuroImmune Pharmaco : Off J Soc NeuroImmune Pharmacol 2:178-183
56. Rosselli M, Ardila A, Lubomski M, Murray S, King K (2001) Personality profile and neuropsychological test performance in chronic cocaine-abusers. The International journal of neuroscience 110:55-72 (Pubitemid 32961627)
57. Rumbaugh JA, Nath A (2006) Developments in HIV neuropathogenesis. Curr Pharm Des 12:1023-1044
58. Sa MJ, Madeira MD, Ruela C, Volk B, Mota-Miranda A, Paula-Barbosa MM (2004) Dendritic changes in the hippocampal formation of AIDS patients: a quantitative Golgi study. Acta Neuropathol 107:97-110 (Pubitemid 38165259)
59. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of neurovirology 8:136-142.
60. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P (2011) HIV-1 infection and cognitive impairment in the cART era: a review. Aids 25:561-575.
61. Shapshak P, Kangueane P, Fujimura RK, Commins D, Chiappelli F, Singer E, Levine AJ, Minagar A, Novembre FJ, Somboonwit C, Nath A, Sinnott JT (2011) Editorial neuroAIDS review. Aids 25:123-141
62. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW (2011) Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. The Journal of infectious diseases 204:753-760, PMC: 3156103
63. Suh HS, Gelman BB, Lee SC (2014) Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 9:117-132, PMC: 3930627
64. Tan IL, McArthur JC (2012) HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 26:123-134
65. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367:188-193 (Pubitemid 24031702)
66. Verdejo-Garcia A, Perez-Garcia M (2007) Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology 190:517-530 (Pubitemid 46204469)
67. Viviani B, Gardoni F, Bartesaghi S, Corsini E, Facchi A, Galli CL, Di Luca M, Marinovich M (2006) Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J Biol Chem 281:30212-30222 (Pubitemid 44537028)
68. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS (1999) A prospective study of HIV disease progression in female and male drug users. Aids 13:257-262 (Pubitemid 29050414)
69. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL (2011) Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci 14:1160-1166, PMC: 3164946
70. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG, Coutts A, Forrester JV (2007) Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82:532-541 (Pubitemid 47367143)